3097 Safety and efficacy of first-line nivolumab (NIVO) and ipilimumab (IPI) in non-small cell lung cancer (NSCLC)
Hellmann, M.D, Rizvi, N, Gettinger, S.N, Goldman, J, Chow, L.Q, Juergens, R, Borghaei, H, Brahmer, J, Shen, Y, Harbison, C.T, Nathan, F, Ready, N.E, Antonia, S.J
Published in European journal of cancer (1990) (01.09.2015)
Published in European journal of cancer (1990) (01.09.2015)
Get full text
Journal Article
3096 First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and biomarker analyses
Gettinger, S.N, Hellmann, M.D, Shepherd, F.A, Antonia, S.J, Brahmer, J, Chow, L.Q, Goldman, J, Juergens, R, Borghaei, H, Ready, N.E, Gerber, D.E, Nathan, F, Shen, Y, Harbison, C.T, Rizvi, N
Published in European journal of cancer (1990) (01.09.2015)
Published in European journal of cancer (1990) (01.09.2015)
Get full text
Journal Article
3010 Phase, randomized trial (CheckMate 057) of nivolumab (NIVO) vs docetaxel (DOC) in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): Subgroup analyses and patient reported outcomes (PROs)
Horn, L, Brahmer, J, Reck, M, Borghaei, H, Spigel, D.R, Steins, M, Ready, N.E, Chow, L.Q, Vokes, E.E, Felip, E, Holgado, E, Barlesi, F, Kohlhäufl, M.J, Burgio, M.A, Fayette, J, Gettinger, S.N, Harbison, C.T, Li, A, Finckenstein, F.G, Paz-Ares, L
Published in European journal of cancer (1990) (01.09.2015)
Published in European journal of cancer (1990) (01.09.2015)
Get full text
Journal Article
Long-term Survival, Clinical Activity, and Safety of Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC)
Gettinger, S.N, Horn, L, Gandhi, L, Spigel, D.R, Antonia, S.J, Rizvi, N.A, Powderly, J.D, Heist, R.S, Carvajal, R.D, Jackman, D.M, Sequist, L.V, Smith, D.C, Leming, P.D, Topalian, S.L, Hodi, F, Sznol, M, Harbison, C.T, Kollia, G.D, Brahmer, J.R
Published in International journal of radiation oncology, biology, physics (01.11.2014)
Published in International journal of radiation oncology, biology, physics (01.11.2014)
Get full text
Journal Article
9001 ORAL A Retrospective Subgroup Analysis of EGFR Immunohistochemistry (IHC) Expression by Histo-Score Correlated to Outcomes From the BMS099 1st Line Phase III NSCLC Trial of Cetuximab (Cet) Plus Carboplatin/Taxane
Lynch, T, Bhagavatheeswaran, P, Mukhopadhyay, P, Khambata-Ford, S, Harbison, C.T
Published in European journal of cancer (1990) (2011)
Published in European journal of cancer (1990) (2011)
Get full text
Journal Article
Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti–PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations
Ascierto, P.A., Bono, P., Bhatia, S., Melero, I., Nyakas, M.S., Svane, I-M., Larkin, J., Gomez-Roca, C., Schadendorf, D., Dummer, R., Marabelle, A., Hoeller, C., Maurer, M., Harbison, C.T., Mitra, P., Suryawanshi, S., Thudium, K., Muñoz Couselo, E.
Published in Annals of oncology (01.09.2017)
Published in Annals of oncology (01.09.2017)
Get full text
Journal Article
Nivolumab (NIVO) in patients (pts) with advanced (adv) chemotherapy-refractory (CT-Rx) esophagogastric (EG) cancer according to microsatellite instability (MSI) status: checkmate 032
Ott, P.A., Le, D.T., Kim, J.W., Ascierto, P.A., Sharma, P., Bono, P., Peltola, K., Jäger, D., Evans, T.R.J., de Braud, F., Chau, I., Bendell, J.C., Tschaika, M., Harbison, C.T., Zhao, H., Calvo, E., Janjigian, Y.
Published in Annals of oncology (01.09.2017)
Published in Annals of oncology (01.09.2017)
Get full text
Journal Article
Characterization of the immune tumor microenvironment (TME) to inform personalized medicine with immuno-oncology (IO) combinations
Luke, J.J., Edwards, R., Hedvat, C., Pandya, D., Ely, S., Meier, R., McDonald, D., Harbison, C.T., Baxi, V., Lee, G., Szabo, P., Garcia, T., Bao, R., Reilly, T.P., Jaffee, E., Hodi, F.S.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
417O Phase 3, randomized trial (CheckMate 057) of nivolumab vs docetaxel in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): subgroup analyses and patient reported outcomes (PROs)
Horn, L., Brahmer, J., Reck, M., Borghaei, H., Spigel, D.R., Steins, M., Ready, N.E., Chow, L.Q., Vokes, E.E., Felip, E., Holgado, E., Barlesi, F., Kohlhäufl, M., Burgio, M.A., Fayette, J., Gettinger, S.N., Harbison, C.T., Li, A., Finckenstein, F.G., Paz-Ares, L.
Published in Annals of oncology (01.12.2015)
Published in Annals of oncology (01.12.2015)
Get full text
Journal Article
Long-term Survival, Clinical Activity, and Safety of Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC): Metastatic Non-Small Cell Lung Cancer
Gettinger, S.N., Horn, L., Gandhi, L., Spigel, D.R., Antonia, S.J., Rizvi, N.A., Powderly, J.D., Heist, R.S., Carvajal, R.D., Jackman, D.M., Sequist, L.V., Smith, D.C., Leming, P.D., Topalian, S.L., Hodi, F., Sznol, M., Harbison, C.T., Kollia, G.D., Brahmer, J.R.
Published in International journal of radiation oncology, biology, physics (15.11.2014)
Published in International journal of radiation oncology, biology, physics (15.11.2014)
Get full text
Journal Article